Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
The beta-blockers comprise a group of drugs that are mostly used to treat cardiovascular disorders such as hypertension, cardiac arrhythmia, or ischemic heart disease. Each of these drugs possesses at least one chiral center, and an inherent high degree of enantioselectivity in binding to the beta-adrenergic receptor. For beta-blockers with a single chiral center, the (-) enantiomer possesses much greater affinity for binding to the beta-adrenergic receptors than antipode. The enantiomers of some of these drugs possess other effects, such as antagonism at alpha-adrenergic receptors or Class III antiarrhythmic activity. However, these effects generally display a lower level of stereoselectivity than the beta-blocking activity. Except for timolol, all of these drugs used systemically are administered clinically as the racemate. As a class, the beta blockers are quite diverse from a pharmacokinetic perspective, as they display a high range of values in plasma protein binding, percent of drug eliminated by metabolism or unchanged in the urine, and in hepatic extraction ratio. With respect to plasma concentrations attained after oral or intravenous dosing, in most cases the enantiomers of the beta-blockers show only a modest degree of stereoselectivity. However, the relative magnitude of the concentrations of the enantiomers in plasma is not constant in all situations and varies from drug to drug. Further, various factors related to the drug (e.g., dosing rate or enantiomer-enantiomer interaction) or the patient (e.g., racial background, cardiovascular function, or the patient metabolic phenotype) may affect the stereospecific pharmacokinetics and pharmacodynamics of beta-blockers. An understanding of the stereospecific pharmacokinetics and pharmacodynamics of beta-blockers may help clinicians to interpret and predict differences among patients in pharmacologic responses to these drugs.
Mehvar
R
R
School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA. rmehvar@ama.ttuhsc.edu
Brocks
D R
DR
D000042:Absorption; D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D000367:Age Factors; D001262:Atenolol / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008790:Metoprolol / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008968:Molecular Conformation; D011412:Propanolamines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011433:Propranolol / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D012737:Sex Factors; D014018:Tissue Distribution
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D001262:Atenolol; D011433:Propranolol; D008790:Metoprolol; C036604:esmolol